Brief: Pds Biotech Announces 100% Clinical Response In Cervical Cancer Patients In Mid-stage Study
14/11/2022 12:51
Nov 14 (Reuters) - Pds Biotechnology Corp PDSB.O :
* PDS BIOTECH ANNOUNCES 100% CLINICAL RESPONSE IN CERVICAL
CANCER
PATIENTS IN PRELIMINARY DATA FROM IMMUNOCERV PHASE 2 CLINICAL
TRIAL
* 89% (8/9) HAD NO EVIDENCE OF DISEASE (COMPLETE RESPONSE)
ON DAY
170
Source text for Eikon: ID:nGNX5NN75V
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing